Epysqli Alternatives Compared
| Epysqli (eculizumab) | Ultomiris (ravulizumab) | Soliris (eculizumab) |
|
|---|
| Epysqli (eculizumab) | Ultomiris (ravulizumab) | Soliris (eculizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Epysqli may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Soliris may also be used for purposes not listed in this... View more |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
Hemolytic Uremic Syndrome
|
|||||||||||||||||||||||
| More about Epysqli (eculizumab) | More about Ultomiris (ravulizumab) | More about Soliris (eculizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Soliris has an average rating of 7.2 out of 10 from a total of 6 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Epysqli side effects |
View all Ultomiris side effects |
View all Soliris side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Epysqli prices |
View all Ultomiris prices |
View all Soliris prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other eculizumab brands include: Bkemv, Soliris |
N/A |
Other eculizumab brands include: Bkemv, Epysqli | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
354 hours |
1192.8 hours |
354 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 104 drugs are known to interact with Epysqli:
|
A total of 87 drugs are known to interact with Ultomiris:
|
A total of 104 drugs are known to interact with Soliris:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 19, 2024 |
December 21, 2018 |
March 16, 2007 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Voydeya
Voydeya (danicopan) is an oral complement factor D inhibitor that may be used to treat ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.